Figure 5.

Dose dependent of Bcl-2 protein expression levels during satraplatin sustained treatment in CRC cells. A) Following treatment with different satraplatin concentrations, the CRC cell apoptotic fractions were measured by FACScan analysis. The bar indicates that a greater accumulation of apoptotic cells was observed with a clinically relevant satraplatin concentration vs the untreated control cells. Data points indicate the mean percentages of apoptosis fractions from three independent experiments; bars, standard deviation. B) The cellular extracts were subjected to Western blot. Satraplatin treatment resulted in markedly decreased Bcl-2 protein expression. The results shown are representative of at least two independent experiments. Equal loading was confirmed by β-actin detection. ^cP<0.01.